Skip to content
DraconiticResearch
Search Sources API
190,839 studies31 sourcesUpdated 11 min ago
Peer-reviewedCC BYCureus

Treatment-Resistant Psychosis in an Adolescent at Risk of Metabolic Syndrome: A Case Report.

  • Michael Belkin1
  • Jasmin Grewal2
  1. 1Psychiatry and Behavioral Sciences, New York Institute of Technology (NYIT) College of Osteopathic Medicine, Old Westbury, USA.
  2. 2Psychiatry and Behavioral Sciences, Nassau University Medical Center, East Meadow, USA.
Read full textPDFDOICite

Abstract

Management of treatment-resistant psychosis is inherently complex, presenting unique clinical challenges in pediatric populations when metabolic syndrome risk limits pharmacologic options. We report a case of an adolescent with rapid decline and persistent psychotic symptoms despite trials of first-line antipsychotic agents. His refractory clinical course required careful consideration of the relative benefits of other antipsychotic therapies against their potential for significant metabolic adverse effects. Clinical decision-making was further complicated by the need to engage the patient's mother in consent discussions and shared treatment decisions. This case highlights the clinical challenges of treating pediatric treatment-resistant psychosis while balancing psychiatric stabilization, cardiometabolic risks, and family-centered consent.

Related

  1. Steroidomic Differences Among Clozapine, Olanzapine, and Risperidone in Male Patients with First-Episode Psychosis, Including a Treatment-Resistant Schizophrenia Subgroup
    Karel Valeš, Kristína Holubová, Filip Španiel +4
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Full textPsychiatry & mental healthCrossrefEurope PMC
  2. Comparison of Metabolic Dysfunction‐Associated Steatotic Liver Disease Between Individuals With Werner Syndrome and Those With Insulin‐Resistant Type 2 Diabetes: Hepatic Steatosis and Fibrosis Indices
    Makoto Miyabayashi, Masaya Koshizaka, Mayumi Shoji +29
    Geriatrics & gerontology internationalPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. Effects of resistant starch on blood pressure and autonomic function in women with the risk of metabolic syndrome: A randomized double-blind pilot study
    Seok-Hoon Lee, Hyang-Rae Lee, Min-Sook Kang +4
    The Journal of International Medical ResearchPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC
  4. Polyendocrine metabolic ovarian syndrome: a new name to support better treatment.
    Ginevra Mills
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadiennePeer-reviewedCC BY-NC-NDFull textObstetrics, gynaecology & paediatricsEurope PMC
  5. Acute Psychosis and Dissociative Syndrome Following Binge Recreational Nitrous Oxide Use: A Case Report
    Francisco Agostinho, Adriana Moutinho, Catarina K Câmara +1
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{belkin2026treatmentresistant,
  title = {{Treatment-Resistant Psychosis in an Adolescent at Risk of Metabolic Syndrome: A Case Report.}},
  author = {Michael Belkin and Jasmin Grewal},
  journal = {Cureus},
  year = {2026},
  month = sep,
  doi = {10.7759/cureus.116658},
  url = {https://europepmc.org/article/MED/42910034},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Treatment-Resistant Psychosis in an Adolescent at Risk of Metabolic Syndrome: A Case Report.
AU  - Michael Belkin
AU  - Jasmin Grewal
PY  - 2026
DA  - 2026/09/21
JO  - Cureus
DO  - 10.7759/cureus.116658
UR  - https://europepmc.org/article/MED/42910034
AB  - Management of treatment-resistant psychosis is inherently complex, presenting unique clinical challenges in pediatric populations when metabolic syndrome risk limits pharmacologic options. We report a case of an adolescent with rapid decline and persistent psychotic symptoms despite trials of first-line antipsychotic agents. His refractory clinical course required careful consideration of the relative benefits of other antipsychotic therapies against their potential for significant metabolic adverse effects. Clinical decision-making was further complicated by the need to engage the patient's mother in consent discussions and shared treatment decisions. This case highlights the clinical challenges of treating pediatric treatment-resistant psychosis while balancing psychiatric stabilization, cardiometabolic risks, and family-centered consent.
SN  - 2168-8184
ER  -